SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as the community rallies around the idea of tokenizing Satoshi Nakamoto's legacy, calling it the '$BTC of memes'. Bullish sentiment is fueled by the narrative that 'we are all Satoshi', with the community emphasizing the token's relevance and potential for mass adoption within the crypto space.

Futu Holdings Ltd. engages in the provision of digitalized financial services. It offers securities brokerage and wealth management products. The company was founded by Leaf Hua Li in December 2007 and is headquartered in Hong Kong.

Futu Holdings Ltd - ADR

FUTU is trending as Chinese ADRs gain momentum, with community members noting its recent performance and potential for further upside. Optimism stems from positive sentiment around Chinese stocks and the company's strong growth metrics. Some traders are also discussing option strategies, anticipating potential volatility around upcoming earnings.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

PDD is trending due to mixed reactions to earnings, where revenue beat expectations but profit margins declined, sparking debate about its growth potential. Community discussions revolve around the impact of Temu, tariff concerns, and the CEO's cautious outlook, creating both bullish and bearish sentiment. Option flow suggests traders are anticipating a rally, while analysts are adjusting price targets, adding to the stock's volatile trading activity.

SSgA Active Trust - Financial Select Sector SPDR

Financial Select Sector SPDR Fund

XLF is trending due to discussions around technical analysis patterns, particularly "blue box" support zones and Elliott Wave theory, suggesting potential buying opportunities. Community members are actively sharing analysis and actionable alerts, while also weighing in on factors like interest rates, earnings, and potential market corrections influencing the financial sector's outlook. The ETF's behavior around key support and resistance levels is being closely monitored for directional clues.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as the community anticipates a major network upgrade, Crescendo, with potential improvements to scalability and smart contract capabilities. Many are also speculating about potential tier-one exchange listings, believing it could trigger a significant price increase. Discussions also highlight Kaspa's underlying technology, such as its blockDAG architecture, as a key differentiator.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible ($RARI) is trending as traders discuss its potential within the NFT space and recent integration with Aleph Zero, which enables low-cost NFT minting. Community members are actively speculating on possible exchange listings and anticipating a significant price surge due to its low market cap and circulating supply. Some traders are comparing it to past bull runs, noting its potential for rapid gains if volume increases.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community speculates on potential ETF approvals and Ripple's acquisitions, which some believe signal a long-term supply squeeze. Bullish sentiment is fueled by Ripple's CEO encouraging investors to "lock in," alongside discussions about XRP's utility and potential decoupling from Bitcoin. Some traders are eyeing a breakout towards the $3.45 level, while others remain cautious, citing historical patterns and the ongoing government shutdown.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as the community discusses its potential as a faster and cheaper alternative to Bitcoin, especially as Bitcoin transaction fees increase. Recent news around 'Bitcoin Jesus' resolving tax charges, coupled with speculation about altcoin season and potential ETF filings, is also fueling interest. Some traders are pointing to its strong chart and historical patterns, suggesting a possible breakout.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog ($DDOG) is trending as analysts raise price targets ahead of upcoming Q2 earnings, with some anticipating strong cloud growth and AI-powered platform innovations.  The community is closely watching for a potential acquisition of Upwind Security to bolster its cloud security offerings.  Despite positive sentiment, some traders express concern about valuation and potential for volatility around the earnings release.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following segments: North America, Europe, Middle East and Africa (EMEA), Latin America, and Asia. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool ($WHR) is trending as investors anticipate upcoming earnings and a potential Fed rate cut, which could stimulate consumer demand; the report is expected October 27, 2025 before market open. Bullish sentiment is rising amidst speculation about a sale of Whirlpool of India and community discussion of a potential technical breakout, despite existing challenges of weak demand and rising costs. The community is also weighing analyst expectations of declining earnings against the potential for a short squeeze given high institutional ownership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TG Therapeutics, Inc. (TGTX) on Wednesday stated that its board of directors has authorized a new share repurchase program to acquire up to an additional $100 million of the company’s common stock.The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024. Under the previous program, TG Therapeutics repurchased a total of approximately 3.5 million shares of its common stock at an average price of $28.55 per share. CEO Michael S. Weiss <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> that the company repurchased $78 million of the stock in August alone at “highly attractive prices.”TGTX stock gained nearly 2% in Wednesday’s pre-market.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-completion-existing-share-repurchase">said</a> on Wednesday that repurchases under the new program may be made on a time-to-time basis through open market purchases, privately negotiated transactions, or other means.Weiss said that the new repurchase program reflects the company’s conviction that “current market prices do not adequately reflect the multibillion-dollar potential of Briumvi or the long-term growth prospects of TG Therapeutics.”Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.In the <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-tumbles-after-disappointing-q2-but-company-reaffirms-confidence-in-multiple-sclerosis-drug/chrXrTDRdcR">second quarter</a>, Briumvi’s net product revenue totaled $138.8 million, representing 91% growth over the same period last year and accounting for over 98% of the company’s total revenue.TGTX stock is down 1% this year but up approximately 31% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tectonic-stock-soars-pre-market-after-tuesday-sell-off/chwTUeNRd8m">Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

 TG Therapeutics Board Authorizes New $100M Share Repurchase Program

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.

Equity

The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.


TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

 Company News for Aug 5, 2025

TG Therapeutics, Inc. (TGTX) on Monday reaffirmed confidence in its flagship drug Briumvi despite a disappointing second-quarter earnings report.Briumvi is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults. Multiple Sclerosis is a chronic, often disabling, autoimmune disease that affects the brain and spinal cord, disrupting communication between the brain and other parts of the body. The disease symptoms include difficulty walking, blurred vision, and altered sensations in limbs or face.“With multiple growth drivers in place, expanding patient and prescriber bases, increasing brand recognition and the momentum of our media investments, we believe Briumvi is on track to become a multibillion-dollar brand in relapsing MS,” said Adam Waldman, Chief Commercial Officer at TG Therapeutics, on the company’s earnings call while adding that it expects stronger growth from the third quarter (Q3) to the fourth quarter (Q4).The firm also raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. TG Therapeutics is also evaluating Briumvi in the treatment of Myasthenia Gravis and testing subcutaneous Briumvi, allowing self-administration of the drug.The company now sees a total global revenue target of approximately $585 million for the full year 2025, up from its previous guidance of $575 million.&nbsp;On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TGTX">TGTX</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:1336/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_04_at_1_21_31_PM_png_bda23ffe5e.webp" alt="TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits" width="1336" height="132"><figcaption>TGTX's Sentiment Meter and Message Volume as of 1:20 p.m. ET on Aug. 4, 2025 | Source: Stocktwits</figcaption></figure>TGTX stock slid over 16% on Monday following the downbeat earnings. A Stocktwits user believes the drop in stock following the earnings report is an opportunity to buy more.<stembedurl>https://stocktwits.com/Firstcall/message/623650797</stembedurl>Another opined that the drop is not justifiable, given that the company raised its guidance.<stembedurl>https://stocktwits.com/Firstcall/message/623647493</stembedurl>For the second quarter, the company’s total revenue came in at $141.15 million, compared to $73.47 million in the corresponding quarter of 2024, and below an analyst estimate of $147.76 million. Briumvi’s net product revenue alone came in at $138.8 million, representing 91% growth over the same period last year, and accounting for over 98% of the company’s total revenue.Diluted earnings per share came in at $0.17, above the $0.04 reported in Q2 2024, but below an analyst estimate of $0.25.&nbsp;TGTX stock is down by 3% this year but up by 70% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-rivian-to-report-q2-earnings-tomorrow/chrXpf7RdTz">Lucid, Rivian To Report Q2 Earnings Tomorrow: Retail Watches Warily With Mixed Sentiments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.


TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -46.88% and +3.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TGTX News

TGTXTG Therapeutics Inc